Healio

FDA approves self-administered nasal spray for paroxysmal supraventricular tachycardia

Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute ...
MedPage Today on MSN

Etripamil gets FDA approval for at-home tachycardia conversion

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), ...
The Cardiology Advisor

Cardamyst Approved for Self-Treatment of PSVT Episodes

Cardamyst is now FDA approved as a self-administered intranasal treatment for acute episodes of paroxysmal supraventricular tachycardia.
TCTMD

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

The self-administered treatment rapidly converts patients into sinus rhythm and may reduce trips to the hospital.

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (…

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly ...
9NEWS

What is SVT (and why does it impact young people?)

DENVER — Heart disease in young people is certainly possible. Supraventricular tachycardia (SVT) can affect kids, adolescents and young adults. It occurs in about 2 out of every 1,000 people. SVT ...
TCTMD

Catheter Ablation May Be Underused for Supraventricular Tachycardia

Catheter ablation was not the first-line treatment for supraventricular tachycardia (SVT) for most patients referred to a tertiary center, a study shows, with investigators suggesting the procedure is ...